A phase 1/2 study of halk.car T cells for patients with relapsed/refractory high-risk neuroblastoma
Active Project Grant Awarded Last action
- Award ID
- HT9425261E468
- Recipient
-
Dana-Farber Cancer Institute, Inc. UEI DPMGH9MG1X67
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $4,199,798
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 5% complete
- Place of performance
- Boston, MA 02215, USA
Award details come from USAspending.gov.
About this award
The Defense Health Agency awarded Dana-Farber Cancer Institute, Inc. $4.199798 million on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to conduct a Phase 1/2 study of HALK CAR T cells for patients with relapsed/refractory high-risk neuroblastoma. The award funds clinical trial design, patient enrollment, and immunotherapy development activities. Work will be performed in Boston, Massachusetts, with a period of performance through August 31, 2030. Dana-Farber Cancer Institute operates as a nonprofit academic medical research organization affiliated with Harvard Medical School, delivering basic and translational cancer research and immunotherapy development primarily to the National Institutes of Health, the Defense Health Agency, and the Department of Veterans Affairs.
Quick answers
Who received award HT9425261E468?
HT9425261E468 was awarded to Dana-Farber Cancer Institute, Inc. by Defense Health Agency (Department of Defense) on September 1, 2026.
How much is award HT9425261E468 worth?
$4,199,798 has been obligated on HT9425261E468.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award